Success of new treatment halts international blood pressure drug trial

December 08, 2004

An international trial comparing blood-pressure lowering treatments has been stopped early due to the significantly better performance of one of the treatments in the trial.

The 19,000 patient Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) has been comparing a new treatment strategy for hypertension against an old one, in order to discover which is better at preventing various cardiovascular events such as heart attacks and strokes.

The older treatment strategy based on the beta-blocker, atenolol and the thiazide diuretic, bendroflumethiazide was compared with a newer treatment strategy using the calcium channel blocker, amlodipine, and the angiotensin converting enzyme inhibitor, perindopril.

The blood pressure part of trial has been stopped because of cardiovascular benefits in favour of the newer calcium channel blocker plus angiotensin converting enzyme inhibitor treatment when compared with the beta-blocker, atenolol and the thiazide diuretic, bendroflumethiazide.

This announcement signals the end of the main clinical elements of the ASCOT trial, launched in 1997.

ASCOT study co-chairmen Björn Dahlöf, from the Sahlgrenska University Hospital, Östra, Sweden, and Peter Sever from Imperial College London, UK, comment: "This is excellent news for the many people who suffer from high blood pressure. Although at the moment we are unable to provide any definite figures on the effectiveness of the new treatments compared with the old, we have seen important significant differences."

The Steering Committee of ASCOT accepted on 18 November the recommendation of its Data Safety Monitoring Board that the blood pressure arm of the trial should be stopped and the majority of patients have now been informed.

The complete results of the ASCOT trial will be made available when all data up to and including the last individual patient visit have been collected and analysed. Investigators and patients will be informed of the final results of ASCOT when these data become available. The results will be published in the scientific press.

Over the next few months all ASCOT patients will be seen for a final visit, when they will be given advice about future treatment of their hypertension.

Prior to their final visit, all patients are advised to stay on their existing drugs until they see their trial physician, to ensure their blood pressure remains controlled. The ASCOT trial doctors remind patients that sudden withdrawal of any treatment regimen could be harmful to them.

Of over 19,000 patients randomised to the two different blood pressure strategies, approximately 10,000 patients were also randomised to treatment with either atorvastatin or placebo in the ASCOT Lipid Lowering Arm (ASCOT-LLA). The ASCOT-LLA was stopped prematurely in October 2002, as a result of substantial benefits associated with statin use in the prevention of heart attacks and strokes.

The principal sponsor of ASCOT is Pfizer Inc, New York. Support has also been provided by Servier Research Group, Paris and Leo Laboratories, Copenhagen.
-end-
About ASCOT
Launched in 1997, the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) is an independent, investigator-led study aiming to evaluate different treatment strategies to prevent cardiovascular disease in hypertensive patients.

It is being conducted in over 650 general practices or in 32 regional medical centres across the UK, Ireland and the five Nordic countries, Sweden, Finland, Denmark, Norway and Iceland.

Number of patients on the ASCOT trial by country
Denmark (including Iceland) -- 1,567
Finland -- 2,382
Norway 2,226
Sweden 4,069
UK and Ireland 9,098
TOTAL 19,342

With over 19,000 patients across the UK, Ireland and Scandinavia, ASCOT is the largest European based prospective, randomised hypertension trial ever to be conducted.

It is jointly coordinated by Imperial College London (International Centre for Circulatory Health, National Heart and Lung Institute at St Marys Hospital, London) and Scandinavian Coordinating Centre (Scandinavian CRI AB), Göteborg, Sweden.

ASCOT web site: www.ascotstudy.org

Imperial College London

Related Heart Attacks Articles from Brightsurf:

Additional heart imaging valuable for women with unexplained heart attacks
Combining diagnostic imaging methods can detect the underlying cause of heart attack in women who did not have blocked arteries.

How to treat the most common heart attacks
One in five patients die within a year after the most common type of heart attack.

Slow release of two chemicals protects the heart after experimental heart attacks
A novel treatment reduces heart damage after serious heart attacks in two animal models.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Declines in heart attacks greater among men than women
In a study published in the American Heart Association scientific journal Circulation, Kaiser Permanente research scientists report a steady decline in heart attacks for both men and women enrolled in the health system from 2000 to 2014, although that rate of decline slowed among women in the last 5 years of the study.

AI helps predict heart attacks and stroke
Artificial intelligence has been used for the first time to instantly and accurately measure blood flow, in a study led by UCL and Barts Health NHS Trust published in Circulation.

Nanoparticle chomps away plaques that cause heart attacks
Michigan State University and Stanford University scientists have invented a nanoparticle that eats away -- from the inside out -- portions of plaques that cause heart attacks.

Additional heart artery stenting reduces risk of future heart attacks
Research has shown that patients who have had emergency heart attack treatment with heart artery stenting -- and have significant narrowings in their other untreated arteries -- can benefit from additional stenting to help prevent future heart attacks.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Since 1990s, heart attacks have become less deadly, frequent for Americans
Heart attack prevention and outcomes have dramatically improved for American adults in the past two decades, according to a Yale study in JAMA Network Open.

Read More: Heart Attacks News and Heart Attacks Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.